Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Hancock Jaffe Laboratories Inc (HJLI)

Hancock Jaffe Laboratories Inc (HJLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,412
  • Shares Outstanding, K 8,685
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,140 K
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.69
Trade HJLI with:

Options Overview Details

View History
  • Implied Volatility 65.88%
  • Historical Volatility 64.97%
  • IV Percentile 4%
  • IV Rank 5.06%
  • IV High 157.46% on 07/09/21
  • IV Low 61.00% on 09/03/21
  • Put/Call Vol Ratio 0.24
  • Today's Volume 120
  • Volume Avg (30-Day) 482
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,345
  • Open Int (30-Day) 2,251

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.60 +39.34%
on 09/07/21
10.68 -0.84%
on 09/27/21
+2.93 (+38.25%)
since 08/27/21
3-Month
5.36 +97.57%
on 07/19/21
10.68 -0.84%
on 09/27/21
+3.85 (+57.12%)
since 06/25/21
52-Week
4.99 +112.22%
on 05/13/21
17.68 -40.10%
on 12/11/20
-0.03 (-0.28%)
since 09/25/20

Most Recent Stories

More News
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories

HJLI : 10.59 (+6.43%)
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -

HJLI : 10.59 (+6.43%)
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET

HJLI : 10.59 (+6.43%)
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered...

HJLI : 10.59 (+6.43%)
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively

HJLI : 10.59 (+6.43%)
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions

HJLI : 10.59 (+6.43%)
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Live webcast on Tuesday, July 13th at 1:00 PM ET

HJLI : 10.59 (+6.43%)
Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

IRVINE, CA / ACCESSWIRE / April 23, 2021 / (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator...

HJLI : 10.59 (+6.43%)
First U.S. Patent Issues on Hancock Jaffe VenoValve

IRVINE, CA / ACCESSWIRE / April 7, 2021 / (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO)...

HJLI : 10.59 (+6.43%)
Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / April 5, 2021 / (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved...

HJLI : 10.59 (+6.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg...

See More

Key Turning Points

3rd Resistance Point 11.54
2nd Resistance Point 11.11
1st Resistance Point 10.85
Last Price 10.59
1st Support Level 10.16
2nd Support Level 9.73
3rd Support Level 9.47

See More

52-Week High 17.68
Fibonacci 61.8% 12.83
Fibonacci 50% 11.34
Last Price 10.59
Fibonacci 38.2% 9.84
52-Week Low 4.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar